Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Veltuzumab-Rap: Interim Phase I/II data

Interim data from 18 patients in the Phase I portion of an open-label, U.S. Phase I/II trial showed

Read the full 185 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE